Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $8.6720, but opened at $8.33. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.33, with a volume of 415 shares.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SGIOY. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 4.1%

The firm has a market cap of $14.20 billion, a PE ratio of 10.43, a P/E/G ratio of 3.32 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.46 and a current ratio of 1.58. The company has a 50 day simple moving average of $9.38 and a two-hundred day simple moving average of $9.90.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its earnings results on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%.The firm had revenue of $881.71 million for the quarter, compared to analyst estimates of $895.52 million. Analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.